DTIL · Precision BioSciences Inc. Common Stock
View on chartInsiders & Stakes
| JANTZ DEREK Chief Scientific Officer | ▼ Sell | Open Market | 4,055,174 Shares held | 6/8/2022 | View profile |
| Michael Amoroso President and CEO | ▼ Sell | Open Market | 243,392 Shares held | 2/18/2026 | View profile |
| Kelly John Alexander Chief Financial Officer | ▼ Sell | Open Market | 125,883 Shares held | 2/18/2026 | View profile |
| SMITH J. JEFFERSON Chief Research Officer | ▼ Sell | Open Market | 121,926 Shares held | 2/18/2026 | View profile |
| Scimeca Dario General Counsel and Secretary | ▼ Sell | Open Market | 56,457 Shares held | 2/18/2026 | View profile |
| Buehler Kevin Director | ▲ Buy | Option Exercise | 49,137 Shares held | 5/20/2026 | View profile |
| Germano Geno J Director | ▲ Buy | Open Market | 47,492 Shares held | 9/25/2026 | View profile |
| Brown Melinda Director | ▲ Buy | Open Market | 45,481 Shares held | 9/25/2026 | View profile |
| Frankel Stanley Director | ▲ Buy | Open Market | 41,478 Shares held | 9/28/2026 | View profile |
| Pire Shari Lisa | ▲ Buy | Option Exercise | 35,028 Shares held | 5/20/2026 | View profile |
| Barton Shane Principal Accounting Officer | ▲ Buy | Option Exercise | 27,502 Shares held | 6/7/2023 | View profile |
| List Alan Chief Medical Officer | ▼ Sell | Open Market | 4,488 Shares held | 5/2/2024 | View profile |
| Wadsworth Samuel C. | ▲ Buy | Option Exercise | 4,202 Shares held | 5/4/2024 | View profile |
Transaction History
| Frankel Stanley | ▲ Buy | Open Market | 1,000 | $6K | 9/28/2026 |
| Brown Melinda | ▲ Buy | Open Market | 1,135 | $7K | 9/25/2026 |
| Germano Geno J | ▲ Buy | Open Market | 2,609 | $16K | 9/25/2026 |
| Buehler Kevin | ▲ Buy | Option Exercise | 21,000 | — | 5/20/2026 |
| Frankel Stanley | ▲ Buy | Option Exercise | 21,000 | — | 5/20/2026 |
| Brown Melinda | ▲ Buy | Option Exercise | 21,000 | — | 5/20/2026 |
| Pire Shari Lisa | ▲ Buy | Option Exercise | 21,000 | — | 5/20/2026 |
| Germano Geno J | ▲ Buy | Option Exercise | 21,000 | — | 5/20/2026 |
| Michael Amoroso | ▼ Sell | Open Market | 20,559 | $79K | 2/18/2026 |
| Kelly John Alexander | ▼ Sell | Open Market | 8,149 | $31K | 2/18/2026 |
| Scimeca Dario | ▼ Sell | Open Market | 4,925 | $19K | 2/18/2026 |
| SMITH J. JEFFERSON | ▼ Sell | Open Market | 4,925 | $19K | 2/18/2026 |
| Michael Amoroso | ▲ Buy | Option Exercise | 67,797 | $0 | 2/17/2026 |
| Kelly John Alexander | ▲ Buy | Option Exercise | 27,584 | $0 | 2/17/2026 |
| Scimeca Dario | ▲ Buy | Option Exercise | 16,667 | $0 | 2/17/2026 |
| SMITH J. JEFFERSON | ▲ Buy | Option Exercise | 16,667 | $0 | 2/17/2026 |
| Michael Amoroso | ▼ Sell | Open Market | 34,799 | $145K | 1/22/2026 |
| Scimeca Dario | ▼ Sell | Open Market | 8,854 | $36K | 1/21/2026 |
| Kelly John Alexander | ▼ Sell | Open Market | 15,213 | $61K | 1/21/2026 |
| SMITH J. JEFFERSON | ▲ Buy | Option Exercise | 16,219 | — | 1/21/2026 |
| SMITH J. JEFFERSON | ▼ Sell | Open Market | 10,200 | $41K | 1/21/2026 |
| Scimeca Dario | ▲ Buy | Option Exercise | 14,908 | $0 | 1/20/2026 |
| Kelly John Alexander | ▲ Buy | Option Exercise | 3,888 | — | 1/20/2026 |
| Kelly John Alexander | ▲ Buy | Option Exercise | 13,900 | — | 1/20/2026 |
| Kelly John Alexander | ▲ Buy | Option Exercise | 26,575 | — | 1/20/2026 |
| SMITH J. JEFFERSON | ▲ Buy | Option Exercise | 2,500 | — | 1/20/2026 |
| Michael Amoroso | ▲ Buy | Option Exercise | 8,888 | — | 1/20/2026 |
| Michael Amoroso | ▲ Buy | Option Exercise | 37,069 | — | 1/20/2026 |
| Michael Amoroso | ▲ Buy | Option Exercise | 69,421 | — | 1/20/2026 |
| Scimeca Dario | ▲ Buy | Option Exercise | 1,978 | $0 | 1/20/2026 |
| Scimeca Dario | ▲ Buy | Option Exercise | 8,425 | $0 | 1/20/2026 |
| SMITH J. JEFFERSON | ▲ Buy | Option Exercise | 10,447 | — | 1/20/2026 |
| Frankel Stanley | ▲ Buy | Open Market | 2,700 | $13K | 12/16/2025 |
| Germano Geno J | ▲ Buy | Open Market | 3,000 | $14K | 12/16/2025 |
| Brown Melinda | ▲ Buy | Open Market | 1,381 | $7K | 12/15/2025 |
| Michael Amoroso | ▼ Sell | Open Market | 3,409 | $22K | 11/3/2025 |
| Kelly John Alexander | ▼ Sell | Open Market | 1,303 | $8K | 11/3/2025 |
| Scimeca Dario | ▼ Sell | Open Market | 665 | $4K | 11/3/2025 |
| Kelly John Alexander | ▲ Buy | Option Exercise | 3,605 | $0 | 11/2/2025 |
| Scimeca Dario | ▲ Buy | Option Exercise | 1,835 | $0 | 11/2/2025 |
| Michael Amoroso | ▲ Buy | Option Exercise | 9,444 | $0 | 11/2/2025 |
| Frankel Stanley | ▲ Buy | Open Market | 2,700 | $13K | 9/26/2025 |
| Brown Melinda | ▲ Buy | Open Market | 1,400 | $7K | 9/22/2025 |
| Kelly John Alexander | ▼ Sell | Open Market | 14,827 | $63K | 7/3/2025 |
| Brown Melinda | ▲ Buy | Open Market | 1,682 | $7K | 6/25/2025 |
| Buehler Kevin | ▲ Buy | Open Market | 5,076 | $21K | 6/25/2025 |
| Germano Geno J | ▲ Buy | Option Exercise | 9,826 | — | 5/27/2025 |
| Pire Shari Lisa | ▲ Buy | Option Exercise | 9,826 | — | 5/27/2025 |
| Frankel Stanley | ▲ Buy | Option Exercise | 9,826 | — | 5/27/2025 |
| Buehler Kevin | ▲ Buy | Option Exercise | 9,826 | — | 5/27/2025 |
| Brown Melinda | ▲ Buy | Option Exercise | 9,826 | — | 5/27/2025 |
| Buehler Kevin | ▲ Buy | Open Market | 4,523 | $21K | 3/26/2025 |
| Brown Melinda | ▲ Buy | Open Market | 1,839 | $9K | 3/26/2025 |
| Germano Geno J | ▲ Buy | Open Market | 3,250 | $17K | 3/25/2025 |
| Michael Amoroso | ▼ Sell | Open Market | 964 | $5K | 3/24/2025 |
| Michael Amoroso | ▲ Buy | Option Exercise | 3,417 | — | 3/21/2025 |
| SMITH J. JEFFERSON | ▼ Sell | Open Market | 154 | $756 | 3/4/2025 |
| Scimeca Dario | ▼ Sell | Open Market | 272 | $1K | 3/4/2025 |
| SMITH J. JEFFERSON | ▲ Buy | Option Exercise | 519 | — | 3/3/2025 |
| Kelly John Alexander | ▲ Buy | Option Exercise | 1,702 | — | 3/3/2025 |
| Scimeca Dario | ▲ Buy | Option Exercise | 919 | — | 3/3/2025 |
| Scimeca Dario | ▼ Sell | Open Market | 8,928 | $43K | 1/22/2025 |
| SMITH J. JEFFERSON | ▼ Sell | Open Market | 10,287 | $49K | 1/22/2025 |
| Michael Amoroso | ▼ Sell | Open Market | 36,838 | $172K | 1/21/2025 |
| Scimeca Dario | ▲ Buy | Option Exercise | 25,312 | — | 1/20/2025 |
| Kelly John Alexander | ▲ Buy | Option Exercise | 44,368 | — | 1/20/2025 |
| Michael Amoroso | ▲ Buy | Option Exercise | 115,388 | — | 1/20/2025 |
| SMITH J. JEFFERSON | ▲ Buy | Option Exercise | 29,168 | — | 1/20/2025 |
| Germano Geno J | ▲ Buy | Open Market | 3,605 | $16K | 12/30/2024 |
| Buehler Kevin | ▲ Buy | Open Market | 4,320 | $21K | 12/27/2024 |
| Kelly John Alexander | ▲ Buy | Open Market | 2,113 | $10K | 12/27/2024 |
| Brown Melinda | ▲ Buy | Open Market | 3,016 | $14K | 12/26/2024 |
| Kelly John Alexander | ▲ Buy | Open Market | 3,000 | $20K | 11/21/2024 |
| Scimeca Dario | ▼ Sell | Open Market | 588 | $5K | 11/4/2024 |
| Michael Amoroso | ▼ Sell | Open Market | 3,012 | $25K | 11/4/2024 |
| Kelly John Alexander | ▲ Buy | Option Exercise | 3,605 | — | 11/2/2024 |
| Scimeca Dario | ▲ Buy | Option Exercise | 1,836 | $0 | 11/2/2024 |
| Michael Amoroso | ▲ Buy | Option Exercise | 9,443 | — | 11/2/2024 |
| Scimeca Dario | ▼ Sell | Open Market | 93 | $1K | 6/10/2024 |
| SMITH J. JEFFERSON | ▼ Sell | Open Market | 50 | $590 | 6/10/2024 |
| Scimeca Dario | ▲ Buy | Option Exercise | 301 | $0 | 6/7/2024 |
| Kelly John Alexander | ▲ Buy | Option Exercise | 454 | — | 6/7/2024 |
| SMITH J. JEFFERSON | ▲ Buy | Option Exercise | 163 | — | 6/7/2024 |
| Michael Amoroso | ▲ Buy | Grant | 8,334 | $100K | 5/8/2024 |
| Kelly John Alexander | ▲ Buy | Grant | 8,334 | $100K | 5/8/2024 |
| SMITH J. JEFFERSON | ▲ Buy | Grant | 833 | $10K | 5/8/2024 |
| Scimeca Dario | ▲ Buy | Grant | 833 | $10K | 5/8/2024 |
| Pire Shari Lisa | ▲ Buy | Option Exercise | 4,202 | — | 5/4/2024 |
| Buehler Kevin | ▲ Buy | Option Exercise | 4,202 | — | 5/4/2024 |
| Wadsworth Samuel C. | ▲ Buy | Option Exercise | 4,202 | — | 5/4/2024 |
| Germano Geno J | ▲ Buy | Option Exercise | 4,202 | — | 5/4/2024 |
| Frankel Stanley | ▲ Buy | Option Exercise | 4,202 | — | 5/4/2024 |
| Brown Melinda | ▲ Buy | Option Exercise | 4,202 | — | 5/4/2024 |
| List Alan | ▼ Sell | Open Market | 290 | $3K | 5/2/2024 |
| Scimeca Dario | ▼ Sell | Open Market | 272 | $3K | 5/2/2024 |
| SMITH J. JEFFERSON | ▼ Sell | Open Market | 154 | $2K | 5/2/2024 |
| Michael Amoroso | ▼ Sell | Open Market | 1,526 | $16K | 5/2/2024 |
| Kelly John Alexander | ▲ Buy | Option Exercise | 1,702 | — | 5/1/2024 |
| Scimeca Dario | ▲ Buy | Option Exercise | 918 | — | 5/1/2024 |
| SMITH J. JEFFERSON | ▲ Buy | Option Exercise | 519 | — | 5/1/2024 |
| List Alan | ▲ Buy | Option Exercise | 982 | — | 5/1/2024 |
| Michael Amoroso | ▲ Buy | Option Exercise | 3,417 | — | 5/1/2024 |
| List Alan | ▼ Sell | Open Market | 238 | $2K | 4/30/2024 |
| List Alan | ▲ Buy | Option Exercise | 868 | — | 4/26/2024 |
| Kelly John Alexander | ▲ Buy | Grant | 506 | $9K | 2/29/2024 |
| SMITH J. JEFFERSON | ▲ Buy | Grant | 1,006 | $12K | 2/29/2024 |
| SMITH J. JEFFERSON | ▼ Sell | Open Market | 28,000 | $10K | 1/23/2024 |
| Michael Amoroso | ▼ Sell | Open Market | 137,390 | $49K | 1/22/2024 |
| Scimeca Dario | ▼ Sell | Open Market | 21,287 | $8K | 1/22/2024 |
| List Alan | ▼ Sell | Open Market | 21,526 | $8K | 1/22/2024 |
| Kelly John Alexander | ▲ Buy | Option Exercise | 116,690 | — | 1/20/2024 |
| Michael Amoroso | ▲ Buy | Option Exercise | 266,720 | — | 1/20/2024 |
| Scimeca Dario | ▲ Buy | Option Exercise | 59,345 | — | 1/20/2024 |
| List Alan | ▲ Buy | Option Exercise | 60,012 | — | 1/20/2024 |
| SMITH J. JEFFERSON | ▲ Buy | Option Exercise | 75,015 | — | 1/20/2024 |
| Michael Amoroso | ▼ Sell | Open Market | 125,025 | $50K | 11/3/2023 |
| Scimeca Dario | ▼ Sell | Open Market | 16,023 | $6K | 11/3/2023 |
| Michael Amoroso | ▲ Buy | Option Exercise | 283,390 | — | 11/2/2023 |
| Kelly John Alexander | ▲ Buy | Option Exercise | 108,188 | — | 11/2/2023 |
| Scimeca Dario | ▲ Buy | Option Exercise | 55,077 | — | 11/2/2023 |
| Scimeca Dario | ▲ Buy | Grant | 5,443 | $2K | 8/31/2023 |
| SMITH J. JEFFERSON | ▲ Buy | Grant | 5,175 | $2K | 8/31/2023 |
| Kelly John Alexander | ▲ Buy | Grant | 5,951 | $2K | 8/31/2023 |
| Kelly John Alexander | ▲ Buy | Grant | 90,000 | $43K | 8/18/2023 |
| Scimeca Dario | ▼ Sell | Open Market | 13,361 | $10K | 6/8/2023 |
| Kelly John Alexander | ▲ Buy | Option Exercise | 13,635 | — | 6/7/2023 |
| Barton Shane | ▲ Buy | Option Exercise | 6,060 | — | 6/7/2023 |
| Kelly John Alexander | ▲ Buy | Option Exercise | 34,091 | — | 6/7/2023 |
| SMITH J. JEFFERSON | ▲ Buy | Option Exercise | 4,872 | — | 6/7/2023 |
| Scimeca Dario | ▲ Buy | Option Exercise | 22,727 | — | 6/7/2023 |
| Scimeca Dario | ▲ Buy | Option Exercise | 9,044 | — | 6/7/2023 |
| List Alan | ▼ Sell | Open Market | 7,771 | $6K | 4/27/2023 |
| List Alan | ▲ Buy | Option Exercise | 26,027 | — | 4/26/2023 |
| Buehler Kevin | ▲ Buy | Option Exercise | 5,701 | — | 4/11/2023 |
| Michael Amoroso | ▼ Sell | Open Market | 46,999 | $39K | 3/22/2023 |
| Michael Amoroso | ▲ Buy | Option Exercise | 102,535 | — | 3/21/2023 |
| Kelly John Alexander | ▲ Buy | Open Market | 20,000 | $17K | 3/17/2023 |
| Scimeca Dario | ▼ Sell | Open Market | 12,172 | $13K | 3/6/2023 |
| List Alan | ▼ Sell | Open Market | 9,473 | $10K | 3/6/2023 |
| Scimeca Dario | ▲ Buy | Option Exercise | 27,558 | — | 3/3/2023 |
| List Alan | ▲ Buy | Option Exercise | 29,453 | — | 3/3/2023 |
| SMITH J. JEFFERSON | ▲ Buy | Option Exercise | 15,576 | — | 3/3/2023 |
| Kelly John Alexander | ▲ Buy | Option Exercise | 51,071 | — | 3/3/2023 |
| Barton Shane | ▲ Buy | Option Exercise | 12,722 | — | 3/3/2023 |
| Scimeca Dario | ▲ Buy | Grant | 2,163 | $2K | 2/28/2023 |
| SMITH J. JEFFERSON | ▲ Buy | Grant | 12,157 | $12K | 2/28/2023 |
| Kelly John Alexander | ▲ Buy | Grant | 11,605 | $11K | 2/28/2023 |
| Michael Amoroso | ▼ Sell | Open Market | 11,006 | $15K | 10/17/2022 |
| Michael Amoroso | ▲ Buy | Option Exercise | 24,208 | — | 10/15/2022 |
| Kelly John Alexander | ▲ Buy | Open Market | 8,200 | $10K | 9/23/2022 |
| Kelly John Alexander | ▲ Buy | Open Market | 37,037 | $50K | 9/22/2022 |
| Kelly John Alexander | ▲ Buy | Open Market | 33,784 | $51K | 6/22/2022 |
| JANTZ DEREK | ▼ Sell | Open Market | 18,849 | $39K | 6/8/2022 |
| Scimeca Dario | ▼ Sell | Open Market | 9,833 | $20K | 6/8/2022 |
| JANTZ DEREK | ▲ Buy | Option Exercise | 29,545 | — | 6/7/2022 |
| JANTZ DEREK | ▲ Buy | Option Exercise | 12,199 | — | 6/7/2022 |
| Scimeca Dario | ▲ Buy | Option Exercise | 22,727 | — | 6/7/2022 |
| Scimeca Dario | ▲ Buy | Option Exercise | 9,047 | — | 6/7/2022 |
| Kelly John Alexander | ▲ Buy | Option Exercise | 34,090 | — | 6/7/2022 |
| Kelly John Alexander | ▲ Buy | Option Exercise | 13,638 | — | 6/7/2022 |
| Barton Shane | ▲ Buy | Option Exercise | 6,061 | — | 6/7/2022 |
| List Alan | ▼ Sell | Open Market | 7,775 | $16K | 4/27/2022 |
| List Alan | ▲ Buy | Option Exercise | 26,035 | — | 4/26/2022 |
| Kelly John Alexander | ▲ Buy | Open Market | 16,677 | $51K | 3/17/2022 |
| Barton Shane | ▲ Buy | Grant | 761 | $3K | 2/28/2022 |
| Scimeca Dario | ▲ Buy | Grant | 2,049 | $7K | 2/28/2022 |
| Kelly John Alexander | ▲ Buy | Grant | 2,714 | $10K | 2/28/2022 |
| Scimeca Dario | ▲ Buy | Grant | 548 | $6K | 8/31/2021 |
| Kelly John Alexander | ▲ Buy | Grant | 998 | $11K | 8/31/2021 |
| Barton Shane | ▲ Buy | Grant | 604 | $6K | 8/31/2021 |
| Scimeca Dario | ▲ Buy | Grant | 2,748 | $13K | 2/26/2021 |
| Barton Shane | ▲ Buy | Grant | 1,294 | $6K | 2/26/2021 |
| Scimeca Dario | ▲ Buy | Grant | 3,156 | $15K | 8/31/2020 |
| Scimeca Dario | ▲ Buy | Grant | 2,072 | $12K | 2/28/2020 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Precision BioSciences to Present HBV Data at AASLD 2026
Precision BioSciences announced a late-breaking oral presentation for its PBGENE-HBV candidate at the upcoming AASLD The Liver Meeting 2026. This event provides a scheduled future date for the company to share new clinical data, which is a key catalyst for stakeholders tracking the drug's development. The announcement highlights the company's ongoing focus on its hepatitis B virus program.
Precision BioSciences to Present HBV Data at AASLD 2026. Precision BioSciences announced a late-breaking oral presentation for its PBGENE-HBV candidate at the upcoming AASLD The Liver Meeting 2026. This event provides a scheduled future date for the company to share new clinical data, which is a key catalyst for stakeholders tracking the drug's development. The announcement highlights the company's ongoing focus on its hepatitis B virus program.